Apollo Hospitals Enterprise Limited (APOLLOHOSP)
🎯 Key Takeaways
- Apollo Hospitals Enterprise Limited is in a strategic growth phase, transitioning from operational scaling to disciplined expansion with a focus on hospital and digital health services. Management is executing a clear roadmap to become a pan-India healthcare platform, supported by consistent financial performance and targeted capital deployment.
- Revenue grew 2% QoQ to ₹6,606 in Q4FY26.
- ⚠️ 1) Execution risk in large-scale expansion: Commissioning 3,415 beds by FY30 requires flawless capital allocation and operational ramp-up, with delays
📖 The Story
Apollo Hospitals Enterprise Limited is in a strategic growth phase, transitioning from operational scaling to disciplined expansion with a focus on hospital and digital health services. Management is executing a clear roadmap to become a pan-India healthcare platform, supported by consistent financial performance and targeted capital deployment. The company is leveraging its strong margins and cash flows to fund capacity expansion while maintaining profitability.
📰 What's Happening
In Q4 FY26, Apollo Hospitals reported consolidated revenue of ₹66,055 million, up 18% YoY, with EBITDA at ₹10,109 million and PAT at ₹5,292 million. The company commissioned four new hospitals adding 855 beds at a cost of ₹1,590 crore and plans to add 3,415 beds by FY29-FY30 at ₹6,714 crore. Digital health GMV grew 20% to ₹528 crore with 11.4% margin, reaching 47 million registered users and 900,000 daily active users. Management reiterated its target of annualized revenue of ₹250 billion by Q4 FY27 with EBITDA margin of 6.5%-7.0%. These developments reflect a deliberate strategy to scale high-margin services across Tier-1 and metro markets.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,086 | 5,589 | 5,527 | 5,592 | 5,842 | 6,304 | 6,477 | 6,606 |
| Operating Profit | 712 | 854 | 825 | 831 | 892 | 996 | 999 | 1,055 |
| OPM % | 13.3% | 14.6% | 13.8% | 13.8% | 14.6% | 14.9% | 14.9% | 15.3% |
| Net Profit | 316 | 396 | 379 | 415 | 441 | 494 | 516 | 551 |
| EPS | ₹21.23 | ₹26.34 | ₹25.89 | ₹27.10 | ₹30.10 | ₹33.19 | ₹34.94 | ₹36.82 |
Revenue has grown steadily from ₹5,086 million in Q1 FY25 to ₹6,606 million in Q4 FY26, with operating profit margin expanding from 13.3% to 15.3% over the same period. Net profit and EPS have risen consistently, reflecting operational efficiency and scale benefits. The 31% YoY growth in EBITDA and 36% growth in PAT in Q4 FY26 underscore margin accretion from expansion initiatives. Management attributes this trajectory to disciplined execution of its hospital and digital health expansion strategy, with profitability expected to sustain as new facilities ramp up.
🔮 Management Outlook & What's Next
Management has provided forward-looking guidance targeting annualized revenue of ₹250 billion by Q4 FY27 and an EBITDA margin of 6.5%-7.0%. It also outlined plans to add 3,415 beds by FY29-FY30 at a total cost of ₹6,714 crore, indicating sustained capital investment in capacity. Digital health is positioned as a key growth lever, with targets to scale GMV and user base while improving unit economics. These targets are tied to operational metrics across 7,289 stores and 167 diagnostic centers, signaling a holistic expansion beyond hospital-led growth.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2024-2025 | 2025-2026 | 2025-2026 | 2025-2026 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 72 | 72 | 72 | 72 | 72 |
| Reserves | 8,140 | — | 9,021 | — | 9,408 |
| Borrowings | 5,275 | — | 5,341 | — | 5,659 |
| Total Liabilities | 12,005 | 6,405 | 12,397 | 6,480 | 12,222 |
| Fixed Assets | 9,816 | — | 9,965 | — | 11,039 |
| Investments | 2,263 | — | 2,780 | — | 1,922 |
| Total Assets | 20,657 | 21,331 | 21,950 | 22,447 | 22,197 |
The balance sheet shows a stable capital structure with equity of ₹72 crore and reserves of ₹9,408 crore in the latest period, supporting total assets of ₹22,197 crore. Borrowings stand at ₹5,659 crore, indicating moderate leverage with a D/E ratio of 0.64. The company is investing capital in expansion (e.g., ₹1,590 crore for new hospitals), but financing is balanced by strong operating cash flows. The presence of reserves and manageable debt suggests capacity to fund growth without dilutive moves or excessive leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 | 2020-2021 |
|---|---|---|
| Operating | +265 | +1,273 |
| Investing | +352 | -872 |
| Financing | -461 | -340 |
| Net Cash Flow | — | — |
⚖️ Peer Comparison — Healthcare Services
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 1.16 L Cr | 64.5 | 20.5% | 21.9% | 0.64 |
| Max Healthcare Institute Limited | 1.02 L Cr | 101.2 | — | — | — |
| Fortis Healthcare Limited | 72,752 | 94.6 | — | — | — |
| Aster DM Healthcare Limited | 39,048 | 7.1 | — | — | — |
| Narayana Hrudayalaya Ltd. | 37,625 | 47.7 | — | — | — |
| Global Health Limited | 33,405 | 65.8 | — | — | — |
| Krishna Institute of Medical Sciences Limited | 30,477 | 80.3 | — | — | — |
| Dr. Lal Path Labs Ltd. | 26,871 | 63.6 | — | — | — |
| Syngene International Limited | 18,295 | 36.3 | — | — | — |
| Dr. Agarwal's Health Care Limited | 14,266 | 88.8 | 14.9% | 6.8% | 0.13 |
⚠️ Risk Factors
1) Execution risk in large-scale expansion: Commissioning 3,415 beds by FY30 requires flawless capital allocation and operational ramp-up, with delays potentially pressuring returns. 2) Competitive pricing pressure in hospital services: As new entrants expand capacity, margins could erode if utilization rates decline or cost control weakens. 3) Regulatory and approval delays: The pending NCLT, SEBI, and shareholder approvals for restructuring schemes introduce uncertainty in timeline and outcome, potentially disrupting strategic momentum.
📋 Recent Filings
-
🔴 Corporate Action 15 June 2026Apollo Hospitals announced a composite scheme of arrangement involving Apollo Healthtech Limited, Transferor Company 1, and Transferor Company 2, seek...
-
🔴 Announcement 30 May 2026Apollo Hospitals announced the resignation of President - Group Oncology and International Dinesh Madhavan, effective close of business on May 30, 202...
-
Announcement 25 May 2026Apollo Hospitals Enterprise Limited announced a shareholder meeting on June 24, 2026, to approve a composite scheme of arrangement involving its demer...
-
🔴 Financial Results 25 May 2026Apollo Hospitals announced its audited financial results for Q4 FY26 and full year ending March 31, 2026, during an earnings call on May 21, 2026. The...
-
🔴 Corporate Action 25 May 2026Apollo Hospitals Enterprise Limited announced a Scheme of Arrangement involving the demerger of its subsidiaries and restructuring of share capital, r...
-
🔴 Corporate Action 21 May 2026Apollo Hospitals Enterprise Limited announced a virtual shareholders' meeting on June 24, 2026, to approve a composite scheme of arrangement involving...
-
🔴 Corporate Action 21 May 2026No summary available
-
🔴 Financial Results 20 May 2026Apollo Hospitals reported consolidated revenue of ₹66,055 million in Q4 FY26, up 18% YoY, with EBITDA rising 31% to ₹10,109 million and PAT growing 36...
-
Announcement 20 May 2026Apollo Hospitals announced a strategic combination between its Apollo Health and Lifestyle Limited (AHLL) maternity and fertility businesses and Kids ...
-
🟡 Board Meeting 20 May 2026Apollo Hospitals announced the outcome of its board meeting, confirming revised turnover and networth figures for ASHPL and AFCPL in Annexure 4, with ...
🧠 Analyst's Read
Apollo Hospitals is executing a well-capitalized growth strategy with improving profitability and expanding digital and physical healthcare infrastructure. Investors should monitor progress on bed addition targets, digital health monetization, and shareholder approval of restructuring initiatives. The next two years will be pivotal in validating the scalability and margin sustainability of its expanded platform.
Based on filing content and financial data. Not a recommendation.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.